Eli Lilly has teamed up with insitro to develop treatments for metabolic diseases, combining insitro’s artificial ...

Less than a year after coming out of stealth mode with a $65 million first-round last year, artificial intelligence specialist Insitro has already signed its first biopharma partner. The South San ...

Founded in 2018, Insitro is part of a growing field of AI companies promising to accelerate drug discovery by using machine learning to analyze huge datasets of chemical and biological markers.

insitro uses machine-learning technology to discover novel drug targets and patient segments. Since its inception in 2018, the company has brought on several high-profile partners and investors.